ALBO News and Press, Albireo Pharma Inc. From 02/26/20

BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Cowen and Company 40...

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on Marc...

In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...

Albireo Pharma (NASDAQ: ALBO) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Last Wednesday, ALBO announced a trio of key clinical updates across three different liver indications, with the most imminent being Ph3 readout for ...

Albireo Pharma ( ALBO ) was spun out from AstraZeneca ( AZN ) and is based in Boston, MA. The company's key flagship molecule is Odevixibat, an inhibitor of ileal bile acid transporter (IBAT), which prevents the reabsorption of bile acids from the ileum back to the liver through the enterohepa...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of i...

Sundial Growers (NASDAQ: SNDL )  -26%  on CEO exit . More news on: Sundial Growers Inc., Briggs & Stratton Corporation, Intelsat S.A., , Stocks on the move, Read more ...

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) is down  11%  premarket on light volume in reaction to its public offering of ~1.9M common shares at $21 per share yielding gross proceeds of ~$40M. More news on: Albireo Pharma, Inc., Healthcare stocks news, Stocks on the ...

BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its commo...